
Studies on zzso use in terminally ill cancer patients have shown a zzso dose increase in the majority of zzso Mostly oral zzso were zzso Due to the zzso properties of zzso it is rather difficult to get a reliable estimate of the true zzso need from those zzso 

zzso we analyzed zzso use during the last week of life of 30 consecutive zzso with cancer on intravenous zzso zzso zzso analgesia zzso A dose increase zzso was defined as an increase zzso of the patient's individual daily dose by at least zzso with respect to their prior daily zzso We also analyzed zzso variations in zzso zzso 

Thirty patients fulfilled the primary study inclusion zzso zzso the exclusion criteria, seven patients had to be excluded from analysis zzso zzso 3, on zzso for less than 7 zzso zzso zzso 4, zzso was finished before zzso zzso patients with a total of 161 treatment days were zzso The patients' median age was 57 years zzso 4 to zzso The median duration of intravenous zzso zzso was 19 days zzso 8 to zzso The median daily intravenous zzso dose during the last week of life was 96 to 115 zzso without significant change over zzso day to day zzso zzso On zzso days zzso zzso dose remained zzso On 9 treatment days zzso the dose increased, and on 8 days zzso it zzso In three patients, only dose increases, and in four patients, only dose decreases were zzso In four patients, both dose increases and decreases were zzso Twelve patients showed no change in daily zzso zzso zzso use lacked a zzso zzso 

During their zzso phase, cancer patients on zzso zzso zzso showed a stable daily zzso zzso 

